HGH Fragment 176-191 vs Tesamorelin

HGH Fragment 176-191 wins for: Side effect profile (nearly placebo-level), no IGF-1 or GH axis perturbation, zero impact on glucose or insulin, no gyno/edema risks, and bulletproof for PCT or stacking with androgenic compounds. Can be run by anyone wanting marginal, targeted subcutaneous fat loss without systemic hormonal shifts.

Tesamorelin wins for: True visceral fat reduction (VAT and hepatic), significant cut in 'GH gut' and fatty liver, clinically proven recomposition effect in humans, larger magnitude of fat loss (especially central fat), and classic GH-peptide synergy (GHRP stacking). Delivers real metabolic-health benefits when indicated for stubborn intra-abdominal fat, but requires monitoring for GH/IGF-1 side effects.

Pick HGH Fragment 176-191 if:

• You want a safe, non-hormonal fat loss adjunct during PCT or in women/low-androgen stacks
• You're chasing stubborn subcutaneous (not visceral) fat, especially for contest prep or localized 'stubborn spots'
• You want minimal sides: no water retention, gyno risk, insulin sensitivity hit, or sleep disruption
• You're stacking with other lipolytics (yohimbine, T3, GLP-1 agonist) and need something with no additive systemic stress
• You want a peptide you can run indefinitely without axis shutdown or complex monitoring

Pick Tesamorelin if:

• Your main goal is visceral fat reduction (GH gut, deep abdominal, or fatty liver/NAFLD)
• You're an experienced user ready to monitor glucose and IGF-1 and want clinically proven results
• You want a GH-peptide stack (tesamorelin + GHRP) for maximal endogenous GH pulsatility and VAT targeting
• You're chasing legit MRI-proven improvements in metabolic health — not just cosmetic leanness
• You can commit to a daily pin and regular bloodwork for a medium-long (20–26 week) cycle